VCYTVERACYTE, INC.
Services-Medical Laboratories
- Revenue
- $517M
- 16% YoY
- Operating margin
- 11.2%
- 209% YoY
- EBITDA
- $79M
- 100% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -3.8×
- −$300M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear205% of net incomeCash flow under 80% of net income
- Dilutive SBCClear8% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyFired52% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $220M | $297M | $361M | $446M | $517M | 16% |
| Operating income | −$82M | −$41M | −$86M | $16M | $58M | 258% |
| Net income | −$76M | −$37M | −$74M | $24M | $66M | 176% |
| Operating cash flow | −$32M | $8M | $44M | $75M | $136M | 82% |
| Capex | $5M | $9M | $10M | $11M | $10M | 14% |
| Stock-based comp | $23M | $27M | $33M | $36M | $44M | 20% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 17
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $7M | $10M | 86 | 125 |
| FY2024 | — | — | 81 | 93 |
| FY2023 | — | — | 56 | 94 |
| FY2022 | — | — | 48 | 90 |
| FY2021 | — | — | 84 | 100 |